Episode Details
Back to EpisodesGlaukos Submits NDA for Epi-On CLX Candidate
Published 1 year, 4 months ago
Description
Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders.
Learn more about your ad choices. Visit megaphone.fm/adchoices